Journey Medical (DERM) - 2023 Q4 - Annual Results

Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of $12.0 million Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Company to hold conferen ...